

Research use only. Not for use in diagnostic procedures.

LANCE® Ultra

Eu-W1024 labeled Anti-phospho-Histone H3 (Thr3) Antibody

Product number: TRF0211-C **Lot Number:** 3369270

Product Format: TRF0211-C: 1.7 μg

Manufacturing date: August 19, 2024 **Document version:** 1

Product Information

Antibody: Europium-labeled rabbit monoclonal antibody recognizing phospho-Thr3 in human Histone H3.

Storage Buffer: 50 mM Tris-HCl (pH 7.4), 0.9% NaCl, 0.1% BSA and 0.05% sodium azide as preservative

Molecular Weight: 160 000

Stability: This product is stable for at least 12 months from the manufacturing date when stored in its

original packaging and at the recommended storage conditions.

Storage Conditions: Store at -20°C. Repeated freezing and thawing should be avoided.

Quality Control

The QC release specifications are based on spectrophotometric analysis of the labeled antibody. We certify that results meet our quality release criteria.

Labeling Ratio: 7.66 Eu/Prot

Concentration: $100 \mu g/ml (0.625 \mu M)$

Recommended Assay Conditions

RSK2 kinase: ATP titration SUGGESTED METHOD:

(Specific applications might require optimization)

Reagent Preparation


- Prepare 1X Kinase Assay Buffer: 50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl₂, 2 mM DTT and 0.01% Tween-20.
- Prepare a 2X RSK2 solution: dilute enzyme to a concentration of 8 nM in 1X Kinase Assay Buffer. Keep on ice.
- Prepare a 4X ULight-Histone H3 (Thr3/Ser10) Peptide solution: dilute ULight-Histone H3 (Thr3/Ser10) Peptide to a concentration of 200 nM in 1X Kinase Assay Buffer.
- Prepare a 4X ATP solution: dilute ATP to concentrations ranging from 40 nM to 4 mM (serial half-log dilutions)
 in Kinase Assay Buffer. Keep on ice.
- Prepare 1X Detection Buffer: dilute 0.5 mL of 10X Detection Buffer with 4.5 mL of H₂O.
- Prepare a 4X Stop solution*: dilute EDTA to a concentration of 40 mM in 1X Detection Buffer.
- Prepare a 4X Detection Mix: dilute Europium-anti-phospho-Histone H3 (Thr3) Antibody to a concentration of 8 nM
 in 1X Detection Buffer.

Protocol

- Pipet 5 µL of 2X RSK2 solution into a 384-well white OptiPlate-384 (4 nM final concentration).
- Add 2.5 μL of 4X ULight-Histone H3 (Thr3/Ser10) Peptide solution (50 nM final concentration).
- Add 2.5 μL of 4X ATP solution (10 nM to 1 mM final concentrations).
- Cover plate with TopSeal-A and incubate 45 min at 23°C.
- Add 5 μL of 4X Stop Solution and incubate 5 min at 23°C.
- Add 5 μL of Detection Mix (2 nM Europium-anti-phospho-Histone H3 (Thr3) Antibody final concentration).
- Cover plate with TopSeal-A and incubate 60 min at 23°C.
- Remove TopSeal-A and read in TR-FRET mode at 665 nm (excitation at 320 or 340 nm).

Typical Product Data

RSK2 kinase assay using ULight-Histone H3 (Thr3/Ser10) Peptide and Eu-anti-phospho-Histone H3 (Thr3) Antibody obtained using the EnVision® Multilabel Reader:



Suggested Materials

Supplier

Substrate: ULight™- Histone H3 (Thr3/Ser10) Peptide Revvity Inc
 Antibody: Eu- anti-phospho-Histone H3 (Thr3) Antibody Revvity Inc

Kinase: RSK2 Carna Biosciences
 Detection Buffer: LANCE® Detection Buffer, 10X Revvity Inc
 Plate: OptiPlate™-384, white Revvity Inc
 TopSeal™-A Revvity Inc

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

TRF0211-C-R Rev01



^{*}Alternatively, the Stop solution and Detection Mix can be premixed and added together to the kinase reaction.

For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.